Physician profile
Blayne E Beene
NPI 1528552130
$1,841.71
in general payments reported to CMS, 2019-2025
28 companies · $600 in 2025
The $600 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.14 · 2021: $172 · 2022: $394 · 2023: $337 · 2024: $328 · 2025: $600.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,265.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,264.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $276.55 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $228.30 | 2023-2025 | Qulipta, Ubrelvy |
| Lilly USA, LLC | $199.06 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $163.98 | 2019-2025 | Airsupra, Breztri |
| Pfizer INC. | $144.36 | 2021-2025 | |
| Glaxosmithkline, LLC. | $139.77 | 2022-2025 | Trelegy Ellipta |
| Otsuka America Pharmaceutical, INC. | $127.78 | 2022-2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $83.72 | 2023-2025 | Xifaxan, Trulance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $67.78 | 2025 | Caplyta |
| Sumitomo Pharma America, INC. | $36.93 | 2025 | Gemtesa |
| Lundbeck LLC | $33.67 | 2023-2024 | Rexulti |
| Exact Sciences Corporation | $28.75 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Boston Scientific Corporation | $28.36 | 2022 | |
| Nevro Corp. | $28.35 | 2022-2024 | Senza |
| Teleflex LLC | $26.35 | 2025 | Urolift |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $23.16 | 2022 | |
| Supernus Pharmaceuticals, INC. | $23.10 | 2024 | Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $22.46 | 2022 | |
| Globus Medical, INC. | $21.64 | 2025 | Senza |
| Sanofi Pasteur INC. | $21.49 | 2022 | |
| Antares Pharma, INC. | $16.68 | 2025 | Xyosted |
| Seqirus USA INC | $16.12 | 2022 | |
| Phathom Pharmaceuticals, INC. | $15.67 | 2024 | Voquezna |
| Idorsia Pharmaceuticals US INC | $14.85 | 2022 | |
| Neurocrine Biosciences, INC. | $14.20 | 2025 | |
| Merck Sharp & Dohme LLC | $13.73 | 2024 | Gardasil 9, Vaxelis, Gardasil |
| Shield Therapeutics INC | $13.24 | 2023 | Accrufer |
| Janssen Pharmaceuticals, INC | $11.66 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Blayne Beene listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.